Pfizer Avoids Japan R&D Layoffs With Creation Of New Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Company spins off part of Nagoya research site into venture-backed RaQualia Pharma.
You may also be interested in...
Pfizer Prunes Its Pipeline And Creates A Stockpile Of Compounds For Deals
Pfizer's latest pipeline refinement shows the drug maker is more than willing to stick with its professed "invest to win" core therapeutic areas after acquiring Wyeth, but the pharma giant is, nonetheless, hedging its bets by keeping some compounds from other areas for the sake of diversity
Pfizer Prunes Its Pipeline And Creates A Stockpile Of Compounds For Deals
Pfizer's latest pipeline refinement shows the drug maker is more than willing to stick with its professed "invest to win" core therapeutic areas after acquiring Wyeth, but the pharma giant is, nonetheless, hedging its bets by keeping some compounds from other areas for the sake of diversity
Pfizer Restructures for a More Flexible Future
In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care, and emerging markets. These units join Pfizer's oncology and mature products businesses.